drugset
drugset / Trial / NCT00160173

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

NCT00160173 ↗

Phase 4 Completed 221 enrolled ASCEND Therapeutics Solvay Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

Timeline

Start
2004-12-02
Primary completion
2005-09-06
Completion
2005-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 0.9 g Topical
Subject Estradiol Other / unclassified 1.25 g Topical

Indications

No indication recorded.